Episodios

  • Is the Testosterone Crisis Real? The Numbers Behind the Headlines | Signal Ep 1

    Is the Testosterone Crisis Real? The Numbers Behind the Headlines | Signal Ep 1
    Apr 14 2026
    Every week there's a new headline saying men are losing testosterone. A quarter of men now start testosterone replacement therapy without ever getting their blood tested. The supplement aisle is full of boosters that either do nothing or contain undisclosed steroids. And the lab test that gets everybody to the pharmacy? Half of low results normalize on their own.In Episode 1 of the Signal launch series, Dr. Jordan Feigenbaum and Dr. Austin Baraki (both MDs and strength coaches) walk through the three-layer problem with how testosterone gets diagnosed and treated in 2026, then take apart the "testosterone is crashing" headline with the most current data available, including a 2025 meta-analysis of more than one million men.Timestamps0:00 Mark's story: treating the number, not the patient1:18 Welcome to the Barbell Medicine Podcast1:41 Problem 1: A quarter of men start TRT with no lab work3:36 Problem 2: Why testosterone boosters do not work (and what is in them)13:40 Problem 3: Why one low testosterone lab is not a diagnosis19:19 Setup: Is the testosterone crisis headline real?20:04 The MMAS data and the 1%-per-year number20:52 The 2025 meta-analysis of over 1 million men22:02 Why the headline is inflated: three causes22:27 Cause 1: The testing method changed (immunoassay to mass spec)25:58 Cause 2: BMI cannot see visceral fat29:37 The Nyante study: when you fix both problems, the decline vanishes33:58 What this actually means for you37:05 The broken testosterone system, summarized38:24 Five takeaways from this episode39:14 Next week: How testosterone actually works39:39 About Signal and creditsWhat you'll learn in this episode: Why 25% of new TRT prescriptions are written without any pre-treatment lab work (JAMA, 2015)What actually happens when researchers test 50+ "testosterone booster" supplements (spoiler: 12% are contaminated with undisclosed steroids)Why a single low testosterone reading is not a diagnosis, and the Massachusetts Male Aging Study data that proves itThe real size of the population-level testosterone decline (much smaller than 1% per year)Why BMI cannot see the visceral fat that is driving most of the genuine declineThe Nyante study that shows the decline essentially vanishes when you use an accurate test and measure waist circumferenceFive practical takeaways you can apply before your next lab drawThis is Episode 1 of a four-part series built around our upcoming book, Signal. Over the next four weeks we cover what testosterone actually is, how to tell when it is genuinely low, what is really driving population-level changes, and what the evidence says you can do about it.Next StepsCheck out our new book, Signal (coming soon)For evidence-based resistance training programs: barbellmedicine.com/training-programsFor individualized training consultation: barbellmedicine.com/coachingExplore our full library of articles on health and performance: barbellmedicine.com/resourcesTo consult with Drs. Baraki or Feigenbaum email us at support@barbellmedicine.comTo support us and get ad free listening, plus special product discounts, and exclusive content, go to supercast.barbellmedicine.comResourcesBaillargeon, J., et al. (2015). Trends in Androgen Prescribing in the United States, 2001–2011. JAMA Intern Med, 175(8), 1413–1415. — 25% no preceding lab; post-prescription monitoring gap.Rao, P.K., et al. (2017). Trends in Testosterone Replacement Therapy Use from 2003 to 2013 among Reproductive-Age Men in the United States. J Urol, 197(4), 1121–1126. — Prescription volume growth.Selinger, S., & Thallapureddy, A. (2024). Cross-sectional analysis of national testosterone prescribing through prescription drug monitoring programs, 2018–2022. PLoS One, 19(8), e0309160. — Recent prescribing data, 3-4 million estimate.Vesper, H.W., et al. (2015). Serum Total Testosterone Concentrations in the US Household Population from the NHANES 2011–2012 Study Population. Clin Chem, 61(12), 1495–1504. — Population testosterone levels, NHANES data.Clemesha, C.G., et al. (2020). "Testosterone Boosting" Supplements Composition and Claims Are Not Supported by the Academic Literature. World J Men's Health, 38(1), 115–122. — 62% no published data, 10% decreased T.Tucker, J., et al. (2018). Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US FDA Warnings. JAMA Network Open, 1(6), e183337. — 12% adulterated with undisclosed steroids.Trost, L.W., & Mulhall, J.P. (2016). Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials. J Sex Med, 13(7), 1029–1046. — Half of low results normalize on repeat.Travison, T.G., et al. (2008). The Natural History of Symptomatic Androgen Deficiency in Men: Onset, Progression, and Spontaneous Remission. JCEM. MMAS data — 50%+ spontaneous normalization.Travison, T.G., et al. (2007). A Population-Level Decline in Serum Testosterone Levels in ...
    Más Menos
    41 m
  • Medical Mystery: The Man Who Got Weaker When He Started Training

    Medical Mystery: The Man Who Got Weaker When He Started Training
    Apr 7 2026
    A 43-year-old man starts exercising and ends up in the ER with a CK over 100x the upper limit of normal. His doctor says it’s from training. We don’t think so. In this episode, Dr. Jordan Feigenbaum and Dr. Austin Baraki walk through the full case — history, labs, diagnosis, and what actually went wrong — then break down the mechanisms behind the answer, the nocebo research, and what the brand-new 2026 guidelines mean for the 40 million Americans on a drug class you’ve definitely heard of.We also cover the STOMP trial (do statins actually impair strength gains?), the SAMSON trial (how much of statin intolerance is nocebo?), the difference between myalgia, myositis, and rhabdomyolysis, Austin’s clinical approach to a patient whose strength is declining on a statin, and the treatment escalation pathway for statin-intolerant patients including bempedoic acid, PCSK9 inhibitors, and inclisiran. Plus, where GLP-1 receptor agonists like tirzepatide fit into the cardiovascular risk picture.Timestamps0:00 — A 43-year-old man is getting weaker, not stronger2:09 — Taking the history: Medications, lifestyle, and red flags12:53 — The labs come back: CK at 18,97916:05 — Metabolic syndrome and the modern treatment approach23:15 — Rhabdomyolysis: What it is and why it’s dangerous29:50 — Final diagnosis and what went wrong with the medications37:15 — 2026 ACC lipid guidelines: What changed40:32 — Three mechanisms: How statins affect muscle47:02 — The nocebo effect and the SAMSON trial54:17 — Do statins impair training? The STOMP trial1:00:30 — Who’s at highest risk for statin muscle problems1:07:36 — What happened to the patient and options if this is you1:14:12 — Five takeawaysFive Takeaway Statin myopathy is real but relatively uncommon. The excess symptom rate above placebo is roughly 1–5% in controlled trials. But in exercising patients, especially on combination therapy, the risk can be higher.There are three proposed mechanisms: reduced energy production from CoQ10 depletion, compromised muscle cell membranes from isoprenoid loss, and accelerated protein breakdown from calcium leak via the ryanodine receptor. Exercise amplifies all three, but the vast majority of people compensate.If you’re on a statin and your strength is going down, talk to your doctor before stopping the medication or changing your training. A CK test can help separate a drug problem from a programming problemThe 2026 ACC guidelines list vigorous exercise as a risk factor for statin-associated muscle symptoms for the first time. They also provide statin-intolerant patients a clear escalation pathway: bempedoic acid, ezetimibe, PCSK9 inhibitors, and more.Lower is better for LDL. There’s a 33% relative reduction in cardiovascular events at <55 vs. 70 mg/dL. Lower for longer. Healthy lifestyle changes plus effective lipid-lowering therapy are among the best things you can do for cardiovascular risk.Next StepsFor evidence-based resistance training programs: barbellmedicine.com/training-programsFor individualized training consultation: barbellmedicine.com/coachingExplore our full library of articles on health and performance: barbellmedicine.com/resourcesTo consult with Drs. Baraki or Feigenbaum email us at support@barbellmedicine.comTo support us and get ad free listening, plus special product discounts, and exclusive content, go to supercast.barbellmedicine.com ResourcesTraining Plateau Action Plan (free):https://www.barbellmedicine.com/training-plateau-action-plan/Fish oil episode:https://open.spotify.com/episode/4kRtXZBMZWKkZPDdIKpu1SLp(a): https://www.barbellmedicine.com/blog/lipoprotein-a-testing-and-treatment/GuidelinesBlumenthal RS, Morris PB, et al. 2026 ACC/AHA Guideline on the Management of Dyslipidemia. Circulation. 2026. DOI: 10.1161/CIR.0000000000001423CaseLászló A, et al. Exercise and Statin-Fibrate Combination Therapy-Caused Myopathy. BMC Research Notes. 2013;6:52. https://pubmed.ncbi.nlm.nih.gov/23388500/ LDL TargetsLee YJ, et al. (Ez-PAVE) Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease. NEJM. 2026. PMID: 41910315Mechanisms of Statin MyopathyMeador BM, Huey KA. Statin-Associated Myopathy and Its Exacerbation with Exercise. Muscle Nerve. 2010;42(4):469–479. https://pubmed.ncbi.nlm.nih.gov/20878737/Safitri N, et al. Statin-Induced Rhabdomyolysis: Mechanisms, Risk Factors, Management. Drug Healthc Patient Saf. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8593596/Molinarolo S, et al. Cryo-electron microscopy reveals sequential binding and activation of Ryanodine Receptors by statin triplets. Nat Commun. 2025;16(1):11508. doi:10.1038/s41467-025-66522-0Thompson PD, et al. Lovastatin Increases Exercise-Induced Skeletal Muscle Injury. Metabolism. 1997;46(10):1206–1210Nocebo Effect and Statin IntoleranceWood FA, et al. N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects (SAMSON). NEJM. 2020;383(22):2182–2184. https://...
    Más Menos
    1 h y 16 m
  • Overtraining Syndrome: Causes, Diagnosis, and What's Actually Going On

    Overtraining Syndrome: Causes, Diagnosis, and What's Actually Going On
    Mar 31 2026
    In 2022, researchers conducted the most rigorous systematic review ever performed on overtraining syndrome — looking specifically for controlled studies that documented a human transitioning from a healthy training state to an overtrained state. Zero studies met those criteria. The word "overtrained" appears in coaching certifications, wearable device dashboards, and clinical sports medicine guidelines — and in each context it means something different. That definitional chaos has consequences: it delays real diagnoses, produces nocebo effects with measurable physiological outcomes, and leads athletes to reduce training they didn't need to reduce.In this episode, Drs. Jordan Feigenbaum and Austin Baraki work through the full evidence base on overtraining syndrome — the taxonomy, the attempted studies, the six competing mechanistic theories, the biomarker failures, and what's actually happening when a lifter can't make progress. Timestamps:0:00 Cold open — the zero-studies finding1:21 Why "overtrained" does four different jobs simultaneously16:10 The FOR / NFOR / OTS taxonomy19:43 The supercompensation model — borrowed from endurance, never validated for resistance training32:28 Austin's clinical differential for fatigue and declining performance36:17 RT evidence — what happens when researchers try to induce OTS through lifting43:19 Austin — what actually drives the complaints he sees in practice47:30 Six theories for what causes overtraining syndrome1:01:09 The biomarker problem — why the T:C ratio and cortisol don't work1:05:09 What your wearable is actually measuring (and what it isn't)1:09:28 Austin — testosterone levels in trained athletes and when to act1:13:40 Heart rate variability — limitations for strength training1:15:36 Session RPE — the monitoring tool that actually works1:17:31 How common is overtraining syndrome, really?1:23:04 Three failure modes — what's actually happening when lifters say they feel overtrained1:32:14 Austin — what a proper medical workup looks like1:34:22 OutroWhat we cover:The definition problem — why a single word is doing four incompatible jobs simultaneously, and why that matters clinically and practically.The taxonomy — functional overreaching, nonfunctional overreaching, and overtraining syndrome as points on a continuous variable that can only be identified after the fact, not at presentation.The supercompensation model — where it came from, why it fails to describe how resistance training adaptation actually works, and how applying it too literally produces both overloading and underloading errors at the same time.Austin's clinical differential — what a physician actually works through when a patient presents with fatigue and declining performance, and where overtraining syndrome actually sits on that list.What resistance training research shows — including 140 maximal singles, 90 working sets per week, and daily 1-rep max attempts. No study has cleanly induced overtraining syndrome through resistance training. The hormonal data went in the opposite direction from what the endurance overtraining model predicts.Six mechanistic theories — glycogen depletion, serotonin/BCAA, autonomic imbalance, central governor, HPA axis dysregulation, and Armstrong's complex systems framework. Each one is partially supported and each falls short.The biomarker problem — resting cortisol is normal in 75%+ of OTS cases, the testosterone to cortisol ratio has never been validated against clinical outcomes as an individual diagnostic, and HRV recovery in strength training lags physical recovery by up to 30 hours.Austin on wearables — including a clinical pattern he's seeing with GLP-1 receptor agonists: wearable scores indicating deterioration when the clinical picture is actually fine.Session RPE as the real tool — why session RPE trending upward at stable training load is a more reliable signal of load-recovery mismatch than any biomarker currently used.Prevalence and confounders — the 60% figure, why it almost certainly captures all three FOR/NFOR/OTS categories plus REDS, depression, and illness, and why the residual true training-load-induced OTS in an otherwise healthy athlete may be vanishingly rare.Three failure modes — the three things Jordan actually sees in practice when lifters present saying they feel overtrained, and how to distinguish between them using session RPE.The medical workup — Austin's practical walkthrough of what to assess when programming and lifestyle changes don't move the needle, including iron deficiency (ferritin testing caveats, lab reference range problems), sleep apnea, post-viral syndromes, and hormone panels done correctly.Next Steps:For evidence-based resistance training programs: barbellmedicine.com/training-programsFor individualized training consultation: barbellmedicine.com/coachingExplore our full library of articles on health and performance: barbellmedicine.com/resourcesTo consult with ...
    Más Menos
    1 h y 36 m
  • Episode #391: VO2 Max vs. Cardiorespiratory Fitness, GLP-1 Costs, and the 10,000-Step Myth | Direct Line March 2026 (Free)

    Episode #391: VO2 Max vs. Cardiorespiratory Fitness, GLP-1 Costs, and the 10,000-Step Myth | Direct Line March 2026 (Free)
    Mar 24 2026

    In this free preview of the March 2026 Direct Line AMA. Drs. Feigenbaum and Baraki cover: VO2 max versus cardiorespiratory fitness for longevity (are Peter Attia’s targets evidence-based? — with Goodhart’s Law and the JAMA evidence), what GLP-1 medications actually cost now via manufacturer programs ($149–449/month), and whether 7,000–10,000 daily steps actually meet the bar for cardiovascular training.


    Full episode for Barbell Medicine Plus subscribers at https://barbellmedicine.supercast.com/


    Timestamps:

    0:00 — Introduction

    3:26 — VO2 Max vs. Cardiorespiratory Fitness for Longevity

    14:11 — GLP-1 Costs: What you should actually be paying now

    21:43 — Is Walking Enough for Cardiovascular Health?


    Next Steps:


    For evidence-based resistance training programs: barbellmedicine.com/training-programs


    For individualized training consultation: barbellmedicine.com/coaching


    Explore our full library of articles on health and performance: barbellmedicine.com/resources


    To consult with Drs. Baraki or Feigenbaum email us at support@barbellmedicine.com


    Resources:


    • JAMA Network Open — Cardiorespiratory Fitness & Long-term Mortality (Mandsager et al.) — Exercise capacity (METs) and longevity — the foundational CRF/mortality study cited in the episode https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2707428
    • JAMA — Blair et al. — Physical fitness and all-cause mortality: a prospective study of healthy men and women https://jamanetwork.com/journals/jama/fullarticle/379243
    • Barbell Medicine Vital Five — Multi-modal CRF benchmarks and longevity targets https://www.barbellmedicine.com/vital-5-action-plan/
    • Lilly Direct — Zepbound (tirzepatide) — Manufacturer direct program ($299–449/month) https://www.lillydirect.com/zepbound
    • NovoCare — Wegovy (semaglutide) — Manufacturer savings program ($149–349/month) https://www.novocare.com/patient/medicines/wegovy.html
    • Orforglipron — Eli Lilly oral GLP-1 — What to know about orforglipron (small-molecule oral GLP-1 agonist, pending FDA approval) https://www.lilly.com/news/stories/what-to-know-about-orforglipron


    Our Sponsors:
    * Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com
    * Check out Factor: http://factormeals.com/bbm50off
    * Check out Quince: https://quince.com/bbm


    Advertising Inquiries: https://redcircle.com/brands

    Privacy & Opt-Out: https://redcircle.com/privacy
    Más Menos
    31 m
  • Episode #390: Why Your Waist Matters More Than Your Weight — The Science of Visceral Fat

    Episode #390: Why Your Waist Matters More Than Your Weight — The Science of Visceral Fat
    Mar 17 2026

    You can have a completely normal BMI and be on your way to cardiovascular disease, type 2 diabetes, and metabolic syndrome without triggering a single alert on a standard health screening. The fat that predicts metabolic risk most accurately isn't the fat your scale or your doctor is tracking. Dr. Jordan Feigenbaum breaks down the science of visceral fat — what it is, how it causes disease, how to measure it correctly at home for free, and what the evidence actually shows about exercise, GLP-1 medications, and testosterone.


    Timestamps:


    • 00:00:00 Cold Open: The Visceral Fat Finding
    • 00:00:49 The Scale Problem — What Body Weight Actually Measures
    • 00:03:50 What Is Visceral Fat — and Why It's Not Just "Belly Fat"
    • 00:05:04 Three Competing Theories: How Visceral Fat Actually Causes Disease
    • 00:08:35 Adipokines: PAI-1, Angiotensinogen, and What Happens When Adiponectin Drops
    • 00:09:52 How to Measure: Three Sites That Don't Give the Same Number
    • 00:14:30 Clinical Thresholds, Ethnic Adjustments, and the Waist-to-Height Ratio
    • 00:15:45 The Weight-to-Waist Ratio: Tracking the Quality of Your Fat Loss
    • 00:19:20 Sleep, Cortisol, and Why the Hormonal Environment Has to Support the Work
    • 00:21:24 Why Exercise Reduces Visceral Fat 6× More Than Diet Alone
    • 00:22:02 Mechanism 1 — Beta-3 Adrenergic Receptors and Preferential Visceral Fat Mobilization
    • 00:24:10 Mechanism 2 — Myokines: The Fat-Burning Signal Only Contracting Muscle Can Send
    • 00:26:21 GLP-1 Agonists and Body Composition: What the Clinical Trials Actually Show
    • 00:28:05 DXA's Blind Spot: Myosteatosis, Glycogen, and Why Lean Mass Numbers Are Inflated
    • 00:30:10 SEMALEAN, the BELIEVE Trial, and the 1-in-10 Reality of Long-Term Lifestyle Programs
    • 00:33:15 Testosterone, Visceral Fat, and the Aromatase Feed-Forward Loop
    • 00:36:05 Three Testosterone Ranges: Deficient, Eugonadal, and Supraphysiological
    • 00:38:05 The Bhasin 4-Group Study — and Why AAS Are a Class, Not a Synonym for TRT
    • 00:39:33 Tesamorelin: The GHRH Analogue That Selectively Targets Visceral Fat
    • 00:40:53 Practical Framework: What to Measure, When, and What to Do
    • 00:43:20 Key Takeaways


    Next Steps


    • For evidence-based resistance training programs: barbellmedicine.com/training-programs
    • For individualized training consultation: barbellmedicine.com/coaching
    • Explore our full library of articles on health and performance: barbellmedicine.com/resources
    • To join Barbell Medicine Plus and get ad-free listening, product discounts, exclusive content, and more: https://barbellmedicine.supercast.com/
    • To consult with Drs. Baraki or Feigenbaum email us at support@barbellmedicine.com
    • Barbell Medicine Vital 5 Action Plan: https://www.barbellmedicine.com/vital-5-action-plan/


    Resources:


    • https://pubmed.ncbi.nlm.nih.gov/11502820/
    • https://pubmed.ncbi.nlm.nih.gov/33567185/
    • https://pubmed.ncbi.nlm.nih.gov/35658024/
    • https://pubmed.ncbi.nlm.nih.gov/40318682/
    • https://pubmed.ncbi.nlm.nih.gov/41068996/
    • https://pubmed.ncbi.nlm.nih.gov/41772149/
    • https://pubmed.ncbi.nlm.nih.gov/23944298/
    • https://pubmed.ncbi.nlm.nih.gov/20948519/
    • https://pubmed.ncbi.nlm.nih.gov/27213481/
    • https://pubmed.ncbi.nlm.nih.gov/23303913/


    Our Sponsors:
    * Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com
    * Check out Factor: http://factormeals.com/bbm50off
    * Check out Quince: https://quince.com/bbm


    Advertising Inquiries: https://redcircle.com/brands

    Privacy & Opt-Out: https://redcircle.com/privacy
    Más Menos
    45 m
  • Episode #389: Your Liver Enzymes Are Elevated — But It Might Not Be Your Liver

    Episode #389: Your Liver Enzymes Are Elevated — But It Might Not Be Your Liver
    Mar 9 2026

    A fit, healthy 39-year-old was nearly sent for a liver biopsy. The cause? Was it that he went to the gym before every blood draw or because his supplement was throwing his labs off?. Dr. Jordan Feigenbaum and Dr. Austin Baraki break down the blind spot that sends thousands of healthy athletes down an expensive, potentially unnecessary diagnostic rabbit hole every year.

    Timestamps:

    • 00:01:09 Introducing the Case
    • 00:03:44 How to Read a Liver Panel: ALT, AST, GGT, Alk Phos, Albumin Explained
    • 00:10:50 What Is GGT and Why Does It Matter Clinically?
    • 00:16:38 Why Exercise, Protein, and Creatine Aren't on the Differential (Yet)
    • 00:17:35 The Workup: Hepatitis Panels, Abdominal Ultrasound, and More
    • 00:19:42 Second Set of Labs — The Mystery Deepens
    • 00:25:25 Updated Differential: What's Still on the List?
    • 00:27:08 The Labs Normalize — A Critical Clue Appears
    • 00:31:40 The Reveal: Exercise Was the Cause All Along
    • 00:32:18 The Mechanism: How Exercise Elevates 'Liver' Enzymes
    • 00:32:54 Point 1 — ALT & AST Are Not Exclusively Liver Enzymes
    • 00:33:49 Point 2 — It's Unavoidable: 100% of Lifters Are Affected
    • 00:36:02 Point 3 — It Takes 10–12 Days to Normalize
    • 00:37:00 Point 4 — It's Mostly Harmless
    • 00:38:27 56% of Physicians Miss This Diagnosis
    • 00:38:48 Why Clinicians Overlook Exercise History
    • 00:44:01 Point 5 — GGT as the Differentiator (And Its Limits)
    • 00:46:42 Why Alkaline Phosphatase Also Rises Post-Workout
    • 00:48:51 The Cost of Missing Lifestyle Context: Over- and Under-Diagnosis
    • 00:53:29 What to Say to Your Doctor: 3 Patient Scripts
    • 00:59:31 5 Key Takeaways
    • 01:00:25 Final Advice from Dr. Baraki


    Next Steps

    • For evidence-based resistance training programs: barbellmedicine.com/training-programs
    • For individualized training consultation: barbellmedicine.com/coaching
    • Explore our full library of articles on health and performance: barbellmedicine.com/resources
    • To join Barbell Medicine Plus and get ad-free listening, product discounts, exclusive content, and more: https://barbellmedicine.supercast.com/
    • To consult with Drs. Baraki or Feigenbaum email us at support@barbellmedicine.com
    • Barbell Medicine Vital 5 Action Plan: https://www.barbellmedicine.com/vital-5-action-plan/


    Resources:

    • Case: https://pubmed.ncbi.nlm.nih.gov/37025214/
    • https://pubmed.ncbi.nlm.nih.gov/29059178/
    • https://pmc.ncbi.nlm.nih.gov/articles/PMC7438350/
    • https://pubmed.ncbi.nlm.nih.gov/18557801/
    • https://pubmed.ncbi.nlm.nih.gov/19209234/
    • https://pubmed.ncbi.nlm.nih.gov/11476029/
    • https://pmc.ncbi.nlm.nih.gov/articles/PMC11165564/
    • https://pmc.ncbi.nlm.nih.gov/articles/PMC12460594/
    • https://pmc.ncbi.nlm.nih.gov/articles/PMC2291230/
    • https://pmc.ncbi.nlm.nih.gov/articles/PMC11319523/
    • https://pmc.ncbi.nlm.nih.gov/articles/PMC3936967/
    • https://pmc.ncbi.nlm.nih.gov/articles/PMC12188904/
    • https://pmc.ncbi.nlm.nih.gov/articles/PMC7969109/
    • https://pmc.ncbi.nlm.nih.gov/articles/PMC11498664/
    • https://pmc.ncbi.nlm.nih.gov/articles/PMC3104191/


    Our Sponsors:
    * Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com
    * Check out Factor: http://factormeals.com/bbm50off
    * Check out Quince: https://quince.com/bbm


    Advertising Inquiries: https://redcircle.com/brands

    Privacy & Opt-Out: https://redcircle.com/privacy
    Más Menos
    1 h y 2 m
  • Episode #388: Muscle Imbalances, Red Meat Risk, and the Science of Body Fat Set Points

    Episode #388: Muscle Imbalances, Red Meat Risk, and the Science of Body Fat Set Points
    Feb 26 2026

    In this special preview of the Barbell Medicine Plus Direct Line, Dr. Jordan Feigenbaum and Dr. Austin Baraki move past the fitness basics to tackle high-level technical nuances. We dive into the persistent myth of "muscle imbalances" and why your asymmetry might actually be a functional feature of your training.

    We also address the "meat" of the cardiovascular debate: is red meat and saturated fat consumption still risky if you are highly active and have a high-fiber diet? Finally, we explore the Dual Intervention Point Model to explain why the body defends its energy stores and how our environment has shifted the biological "set point" for body fat.

    Timestamps
    • 00:00 – Barbell Medicine Plus: Special Annual Membership Promotion
    • 01:03 – Muscle Imbalances: A Reliable Predictor of Pain?
    • 03:59 – Acuted vs. Gradually Acquired Asymmetries
    • 08:55 – How Coaches Should Manage "Alignment" Beliefs
    • 11:54 – Is Red Meat Necessary to Limit if You Are Otherwise Healthy?
    • 15:36 – The Role of Substitution: Plant vs. Animal Protein
    • 19:50 – Analyzing the Lean Mass Hyper-Responder (LMHR) Phenotype
    • 26:20 – The Dual Intervention Point Model of Body Fatness
    • 30:26 – Lipostat, Gravistat, and the Regulation of Energy Stores


    Next Steps
    • For evidence-based resistance training programs: barbellmedicine.com/training-programs
    • For individualized training consultation: barbellmedicine.com/coaching
    • Explore our full library of articles on health and performance: barbellmedicine.com/resources
    • To join Barbell Medicine Plus and get ad-free listening, product discounts, exclusive content, and more: https://barbellmedicine.supercast.com/
    • To consult with Drs. Baraki or Feigenbaum email us at support@barbellmedicine.com
    • Barbell Medicine Vital 5 Action Plan: https://www.barbellmedicine.com/vital-5-action-plan/


    Key Takeaways
    • Asymmetry as a Feature: Human bodies are not naturally symmetrical. In many athletes—such as tennis players, pitchers, or rowers—asymmetry is a functional adaptation to the sport's demands.
    • The Pathological vs. The Normal: Acutely acquired asymmetries (post-surgery or trauma) require specific clinical attention. Long-standing or gradually acquired asymmetries are rarely the primary driver of pain.
    • Saturated Fat & The Healthy User Bias: While fit individuals have a lower overall risk profile, elevated LDL and ApoB particles represent a "time-volume" exposure risk that should not be ignored based solely on lifestyle.
    • The Lean Mass Hyper-Responder (LMHR): We analyze the bold claims surrounding the LMHR phenotype and discuss why mechanistic hypothesizing currently lacks the "hard human outcome receipts" to prove long-term safety.
    • Body Fat Regulation: The Dual Intervention Point Model suggests the body defends a lower boundary (starvation) and an upper boundary (predation). In the modern environment, the "predation pressure" has vanished, leading to a genetic drift upward in body fat set points.






    Our Sponsors:
    * Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com
    * Check out Factor: http://factormeals.com/bbm50off
    * Check out Quince: https://quince.com/bbm


    Advertising Inquiries: https://redcircle.com/brands

    Privacy & Opt-Out: https://redcircle.com/privacy
    Más Menos
    34 m
  • Episode #387: The Valsalva Maneuver- Blood Pressure & Safety in Lifting

    Episode #387: The Valsalva Maneuver- Blood Pressure & Safety in Lifting
    Feb 20 2026
    Most doctors, trainers, and "safety-first" influencers warn that holding your breath while lifting is a dangerous habit that could lead to a stroke or heart failure. By looking back at the 300-year history of the Valsalva maneuver—from a 1704 ear treatment to the "boogeyman" blood pressure studies of the 1980s—we dismantle the myth of the "fragile tube." Discover the science of the "pressurized suit" and why your body is actually designed to handle extreme internal pressure during heavy exertion.Key TakeawaysThe 'Ear Trick' Origins: Originally described in 1704 by Antonio Maria Valsalva as a way to clear middle-ear infections, the maneuver wasn't linked to cardiovascular risk until the 1850s "Weber experiments."The MacDougall 480/350 Study: Why the finding of massive blood pressure spikes during leg presses may have created a "villain arc" for the Valsalva maneuver in modern medicine.Transmural Pressure Protection: A blood vessel fails when internal pressure significantly exceeds external support; during a Valsalva, the internal spike is matched by an external "cradle" of intra-thoracic and cerebrospinal fluid pressure.Reflexive vs. Intentional Bracing: The Valsalva maneuver is a hard-wired reflex that triggers involuntarily at approximately 80% of a maximal voluntary contraction to stabilize the trunk.Vascular Safety and Stroke Risk: Evidence suggests that for healthy populations, the risk of a vascular "pop" is negligible because the pressure gradient across the vessel wall (transmural pressure) remains stable.Pregnancy and Fetal Safety: Clinical data on pregnant athletes shows that heavy, braced lifting up to 90% of a 10-rep max does not cause fetal distress or compromised uterine blood flow.The 'Hissing' Safety Valve: For those prone to lightheadedness or pelvic floor symptoms, using a slow, active exhalation (a hiss) during the concentric phase can help manage pressure transitions.Timestamps[00:00] History: From the 1704 Ear Treatise to the Weber Fainting Experiments[05:26] The 1985 MacDougall Study: Origin of the "480/350" Blood Pressure Boogeyman[06:22] The Anatomy of a Breath-Hold: The 4 Phases of the Valsalva Maneuver[12:59] Reflexive Bracing: Why You Can’t Stop Yourself from Holding Your Breath[28:24] The Pressurized Suit: Transmural Pressure and Vascular Safety[31:00] The Brain and the Box: CSF Protection and Intracranial Pressure[35:27] Heart Health: Does Lifting Cause Pathological Heart Thickening?[41:17] Special Populations: Strokes, Aneurysms, and the 'Pop' Theory[46:15] The Pelvic Floor: Stress Incontinence and the Weightlifter's Paradox[49:34] Pregnancy: Monitoring Fetal Heart Rates During Heavy Braced Lifting[56:42] Contraindications: When is the Valsalva Maneuver Actually Dangerous?Next StepsFor evidence-based resistance training programs: barbellmedicine.com/training-programsFor individualized training consultation: barbellmedicine.com/coachingExplore our full library of articles on health and performance: barbellmedicine.com/resourcesTo join Barbell Medicine Plus and get ad-free listening, product discounts, exclusive content, and more: https://barbellmedicine.supercast.com/To consult with Drs. Baraki or Feigenbaum email us at support@barbellmedicine.com Barbell Medicine Vital 5 Action Plan: https://www.barbellmedicine.com/vital-5-action-plan/ ReferencesMiddle Cerebral Artery and ValsalvaValsalva During Resistance TrainingValsalva and Force Production and WeightIAP During CoughingLifting Belt’s Effects Leg PressTraining and Heart AdaptationsPowerlifter’s HeartsValsalva Maneuver and Cerebrovascular DynamicsRT, VM, and Cerebrovascular PressuresWomen’s Pelvic FloorsPregnancy and RT and AgainFetal Heart RateInjury RiskHerniaSUI PodcastOur Sponsors:* Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com* Check out Factor: http://factormeals.com/bbm50off* Check out Quince: https://quince.com/bbmAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
    Más Menos
    1 h y 12 m